Covid-19: FDA expert panel recommends authorising molnupiravir but also voices concerns

被引：31
作者：
Dyer, Owen
机构：
来源：
BMJ-BRITISH MEDICAL JOURNAL | 2021年 / 375卷
关键词：
D O I：
10.1136/bmj.n2984
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页数：2
相关论文
共 8 条
[1]  
Farley J., 2021, FDA ANT DRUGS ADV CO
[2]  
FDA, 2021, FDA BRIEF DOC ANT DR
[3]  
FDA, 2021, BRIEF DOC ANT DRUGS
[4]  
FDA, 2021, ANTIMICROBIAL DRUGS
[5]   Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports [J].
Mahase, Elisabeth .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 375 :n2713
[6]   Covid-19: UK becomes first country to authorise antiviral molnupiravir [J].
Mahase, Elisabeth .
BMJ-BRITISH MEDICAL JOURNAL, 2021, 375 :n2697
[7]  
Merck, 2021, PFIZ PROV US GOV 10
[8]  
Regeneron, 2021, REG EV REGEN COV NEX
1